BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, Lim SG, Bertoletti A. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2009;137:682-690. [PMID: 19394336 DOI: 10.1053/j.gastro.2009.04.045] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Flecken T, Spangenberg HC, Thimme R. Immunobiology of hepatocellular carcinoma. Langenbecks Arch Surg. 2012;397:673-680. [PMID: 21479622 DOI: 10.1007/s00423-011-0783-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
2 Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Review of Gastroenterology & Hepatology 2014;3:561-9. [DOI: 10.1586/egh.09.48] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
3 Attalla K, Farkas AM, Anastos H, Audenet F, Galsky MD, Bhardwaj N, Sfakianos JP. TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. Urol Oncol 2020:S1078-1439(20)30275-1. [PMID: 32665122 DOI: 10.1016/j.urolonc.2020.06.007] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shuai Z, Leung MW, He X, Zhang W, Yang G, Leung PS, Eric Gershwin M. Adaptive immunity in the liver. Cell Mol Immunol 2016;13:354-68. [PMID: 26996069 DOI: 10.1038/cmi.2016.4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
5 Ma XL, Qu XD, Yang WJ, Wang BL, Shen MN, Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, Gong ZJ, Zhang X, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. Clin Chim Acta 2020;511:67-74. [PMID: 32979338 DOI: 10.1016/j.cca.2020.09.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Witkowski M, Spangenberg HC, Neumann-Haefelin C, Büttner N, Breous E, Kersting N, Drognitz O, Hopt UT, Blum HE, Semmo N, Thimme R. Lack of ex vivo peripheral and intrahepatic α-fetoprotein-specific CD4+ responses in hepatocellular carcinoma. Int J Cancer 2011;129:2171-82. [PMID: 21170957 DOI: 10.1002/ijc.25866] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
7 Patel P, Schutzer SE, Pyrsopoulos N. Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol 2016; 7(3): 242-255 [PMID: 27574562 DOI: 10.4291/wjgp.v7.i3.242] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
8 Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Mol Ther 2018;26:2553-66. [PMID: 30217730 DOI: 10.1016/j.ymthe.2018.08.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
9 Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015;12:292-302. [PMID: 25308752 DOI: 10.1038/cmi.2014.91] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 10.6] [Reference Citation Analysis]
10 Yang M, Yang G, Li F, Ou M, Li C, Chen J, Lin H, Zhang Y, Xue W, Wu Y, Xu Y, Sui W, Dai Y. HBV integrated genomic characterization revealed hepatocyte genomic alterations in HBV-related hepatocellular carcinomas. Mol Clin Oncol 2020;13:79. [PMID: 33062269 DOI: 10.3892/mco.2020.2149] [Reference Citation Analysis]
11 Liu Q, Tian Y, Li Y, Zhang W, Cai W, Liu Y, Ren Y, Liang Z, Zhou P, Zhang Y, Bao Y, Li Y. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma. J Immunother Cancer 2020;8:e001748. [PMID: 33323464 DOI: 10.1136/jitc-2020-001748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Koh S, Tan AT, Li L, Bertoletti A. Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future. Diseases 2016;4:E10. [PMID: 28933390 DOI: 10.3390/diseases4010010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
13 Tan WCC, Nerurkar SN, Cai HY, Ng HHM, Wu D, Wee YTF, Lim JCT, Yeong J, Lim TKH. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun (Lond) 2020;40:135-53. [PMID: 32301585 DOI: 10.1002/cac2.12023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 26.5] [Reference Citation Analysis]
14 Lote H, Cafferkey C, Chau I. PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treat Rev. 2015;41:893-903. [PMID: 26412280 DOI: 10.1016/j.ctrv.2015.09.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
15 Lim JCT, Yeong JPS, Lim CJ, Ong CCH, Wong SC, Chew VSP, Ahmed SS, Tan PH, Iqbal J. An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use. Pathology 2018;50:333-41. [PMID: 29429740 DOI: 10.1016/j.pathol.2017.11.087] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
16 Wang G, Li Z, Tian H, Wu W, Liu C. Modification of sPD1 with CRT induces potent anti-tumor immune responses in vitro and in vivo. Biomed Pharmacother 2015;76:57-64. [PMID: 26653551 DOI: 10.1016/j.biopha.2015.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Behboudi S, Alisa A, Boswell S, Anastassiou J, Pathan AA, Williams R. Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease. Br J Cancer 2010;102:748-53. [PMID: 20087354 DOI: 10.1038/sj.bjc.6605526] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
18 Seifi-Alan M, Shamsi R, Ghafouri-Fard S. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma. Immunotherapy 2018;10:411-21. [PMID: 29473472 DOI: 10.2217/imt-2017-0154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
19 Winkler F, Bengsch B. Use of Mass Cytometry to Profile Human T Cell Exhaustion. Front Immunol 2019;10:3039. [PMID: 32038613 DOI: 10.3389/fimmu.2019.03039] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
20 Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, Deng L, Wang Y, Zhang X, Jiang T, Lu X. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. J Immunother 2016;39:171-80. [PMID: 27070448 DOI: 10.1097/CJI.0000000000000122] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
21 Tauber C, Schultheiss M, Luca R, Buettner N, Llewellyn-Lacey S, Emmerich F, Zehe S, Price DA, Neumann-Haefelin C, Schmitt-Graeff A, Hofmann M, Thimme R. Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma. Oncotarget. 2019;10:5194-5206. [PMID: 31497249 DOI: 10.18632/oncotarget.27146] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
22 Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128:887-896. [PMID: 20473887 DOI: 10.1002/ijc.25397] [Cited by in Crossref: 252] [Cited by in F6Publishing: 257] [Article Influence: 22.9] [Reference Citation Analysis]
23 Zhao Q, Huang ZL, He M, Gao Z, Kuang DM. BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma. Oncoimmunology 2016;5:e1254855. [PMID: 28123898 DOI: 10.1080/2162402X.2016.1254855] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
24 Xu Y, Li H, Gao RL, Adeyemo O, Itkin M, Kaplan DE. Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clin Immunol 2011;139:302-13. [PMID: 21419713 DOI: 10.1016/j.clim.2011.02.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
25 Park HJ, Kusnadi A, Lee EJ, Kim WW, Cho BC, Lee IJ, Seong J, Ha SJ. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol 2012;278:76-83. [PMID: 23121978 DOI: 10.1016/j.cellimm.2012.07.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
26 Behboudi S, Boswell S, Williams R. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma. Liver Int. 2010;30:521-526. [PMID: 20040052 DOI: 10.1111/j.1478-3231.2009.02194.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
27 Yang ZQ, Yang ZY, Zhang LD, Ping-Bie SG, Ma KS, Li XW, Dong JH. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients. Hum Immunol. 2010;71:1180-1186. [PMID: 20870003 DOI: 10.1016/j.humimm.2010.09.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
28 Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234:8509-8521. [PMID: 30520029 DOI: 10.1002/jcp.27782] [Cited by in Crossref: 258] [Cited by in F6Publishing: 262] [Article Influence: 64.5] [Reference Citation Analysis]
29 Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, Pelosi G, Schianchi C, Soliani P, Campanini N, Silini EM, Trenti T, Ferrari C, Missale G. Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One 2012;7:e32493. [PMID: 22396772 DOI: 10.1371/journal.pone.0032493] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
30 Mohsenzadegan M, Nowroozi MR, Fotovvat A, Bavandpour Baghshahi P, Bokaie S, Inanloo SH, Sharifi L. The prospect of targeting T cell immunoglobulin and mucin-domain containing-3 in renal cell carcinoma immunotherapy. Scand J Immunol 2022;:e13197. [PMID: 35700044 DOI: 10.1111/sji.13197] [Reference Citation Analysis]
31 Sun C, Lan P, Han Q, Huang M, Zhang Z, Xu G, Song J, Wang J, Wei H, Zhang J, Sun R, Zhang C, Tian Z. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion. Nat Commun 2018;9:1241. [PMID: 29593314 DOI: 10.1038/s41467-018-03584-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
32 Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunotherapy Advances 2022;2:ltab026. [DOI: 10.1093/immadv/ltab026] [Reference Citation Analysis]
33 Xu P, Chen YJ, Chen H, Zhu XY, Song HF, Cao LJ, Wang XF. The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver. 2014;8:186-195. [PMID: 24672661 DOI: 10.5009/gnl.2014.8.2.186] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
34 Chen W, Liu P, Wang Y, Nie W, Li Z, Xu W, Li F, Zhou Z, Zhao M, Liu H. Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma. PLoS One 2013;8:e76965. [PMID: 24194851 DOI: 10.1371/journal.pone.0076965] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
35 Han Y, Wu Y, Yang C, Huang J, Guo Y, Liu L, Chen P, Wu D, Liu J, Li J, Zhou X, Hou J. Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy. J Transl Med 2017;15:64. [PMID: 28330473 DOI: 10.1186/s12967-017-1165-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
36 Koh S, Shimasaki N, Bertoletti A. Redirecting T Cell Specificity Using T Cell Receptor Messenger RNA Electroporation. Methods Mol Biol 2016;1428:285-96. [PMID: 27236807 DOI: 10.1007/978-1-4939-3625-0_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
37 Cheng Y, Gunasegaran B, Singh HD, Dutertre C, Loh CY, Lim JQ, Crawford JC, Lee HK, Zhang X, Lee B, Becht E, Lim WJ, Yeong J, Chan CY, Chung A, Goh BK, Chow PK, Chan JK, Ginhoux F, Tai D, Chen J, Lim SG, Zhai W, Choo SP, Newell EW. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021;54:1825-1840.e7. [DOI: 10.1016/j.immuni.2021.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Bertoletti A, Brunetto M, Maini MK, Bonino F, Qasim W, Stauss H. T cell receptor-therapy in HBV-related hepatocellularcarcinoma. Oncoimmunology 2015;4:e1008354. [PMID: 26155416 DOI: 10.1080/2162402X.2015.1008354] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
39 Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S. Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma. PLoS One 2014;9:e88133. [PMID: 24520352 DOI: 10.1371/journal.pone.0088133] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
40 Li N, Fan X, Wang X, Deng H, Zhang K, Zhang X, Han Q, Lv Y, Liu Z. PRDM1 rs1010273 polymorphism is associated with overall survival of patients with hepatitis B virus-related hepatocellular carcinoma. Immunol Lett 2019;213:39-45. [PMID: 31376415 DOI: 10.1016/j.imlet.2019.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, Blum HE, Neumann-Haefelin C, Thimme R. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 2014;59:1415-26. [PMID: 24002931 DOI: 10.1002/hep.26731] [Cited by in Crossref: 205] [Cited by in F6Publishing: 199] [Article Influence: 25.6] [Reference Citation Analysis]
42 Siu EH, Chan AW, Chong CC, Chan SL, Lo KW, Cheung ST. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Transl Gastroenterol Hepatol. 2018;3:89. [PMID: 30603725 DOI: 10.21037/tgh.2018.10.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
43 Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. Gastroenterology 2015;149:1042-52. [PMID: 26052074 DOI: 10.1053/j.gastro.2015.05.055] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 7.6] [Reference Citation Analysis]
44 Han Y, Li H, Guan Y, Huang J. Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma. Cancer Letters 2016;379:206-12. [DOI: 10.1016/j.canlet.2015.06.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
45 Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, Kagaya T, Yamashita T, Honda M, Kaneko S. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 2011;53:1206-16. [PMID: 21480325 DOI: 10.1002/hep.24149] [Cited by in Crossref: 123] [Cited by in F6Publishing: 118] [Article Influence: 11.2] [Reference Citation Analysis]
46 Wang JJ, Burger P, Taube J, Soni A, Chaichana K, Sheu M, Belcaid Z, Jackson C, Lim M. PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors. Cureus 2019;11:e6352. [PMID: 31938638 DOI: 10.7759/cureus.6352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Lu JC, Zeng HY, Sun QM, Meng QN, Huang XY, Zhang PF, Yang X, Peng R, Gao C, Wei CY, Shen YH, Cai JB, Dong RZ, Shi YH, Sun HC, Shi YG, Zhou J, Fan J, Ke AW, Yang LX, Shi GM. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. Theranostics 2019;9:4678-87. [PMID: 31367249 DOI: 10.7150/thno.36276] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
48 Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, Knuth A, Boehmer Lv, Broek Mv. γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One 2011;6:e28217. [PMID: 22140550 DOI: 10.1371/journal.pone.0028217] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 8.2] [Reference Citation Analysis]
49 Raufi A, Tirona MT. Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. Cancer Manag Res 2017;9:19-27. [PMID: 28223846 DOI: 10.2147/CMAR.S111673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
50 Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. Journal of Hepatology 2011;54:830-4. [DOI: 10.1016/j.jhep.2010.10.013] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 6.0] [Reference Citation Analysis]
51 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
52 Schmidt N, Neumann-Haefelin C, Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig Dis. 2012;30:483-491. [PMID: 23108304 DOI: 10.1159/000341697] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
53 Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1922. [PMID: 33923463 DOI: 10.3390/cancers13081922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Zhao Y, Xue F, Sun J, Guo S, Zhang H, Qiu B, Geng J, Gu J, Zhou X, Wang W, Zhang Z, Tang N, He Y, Yu J, Xia Q. Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma. Clin Epigenetics 2014;6:30. [PMID: 25859288 DOI: 10.1186/1868-7083-6-30] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
55 Reiser J, Banerjee A. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. J Immunol Res 2016;2016:8941260. [PMID: 27314056 DOI: 10.1155/2016/8941260] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 12.5] [Reference Citation Analysis]
56 Li KK, Adams DH. Antitumor CD8+ T cells in hepatocellular carcinoma: present but exhausted. Hepatology 2014;59:1232-4. [PMID: 24123091 DOI: 10.1002/hep.26779] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
57 Watanabe T, Bertoletti A, Tanoto TA. PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat 2010;17:453-8. [PMID: 20487259 DOI: 10.1111/j.1365-2893.2010.01313.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 48] [Article Influence: 0.8] [Reference Citation Analysis]
58 Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, Takeishi K, Ijichi H, Harada N, Uchiyama H, Yoshizumi T, Taketomi A, Maehara Y. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J Clin Oncol 2010;15:552-8. [DOI: 10.1007/s10147-010-0131-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
59 Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini MK, Bonino F, Stauss H, Bertoletti A. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91. [PMID: 25308176 DOI: 10.1016/j.jhep.2014.10.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 102] [Article Influence: 13.0] [Reference Citation Analysis]
60 Li W, Qi Y, Xu H, Wei W, Cui X. Profile of different Hepatitis B virus integration frequency in hepatocellular carcinoma patients. Biochem Biophys Res Commun 2021;553:160-4. [PMID: 33773138 DOI: 10.1016/j.bbrc.2021.03.056] [Reference Citation Analysis]
61 Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117:4501-4510. [PMID: 21385853 DOI: 10.1182/blood-2010-10-310425] [Cited by in Crossref: 383] [Cited by in F6Publishing: 374] [Article Influence: 34.8] [Reference Citation Analysis]
62 Lawrenczyk A, Kim S, Wen X, Xiong R, Yuan W. Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment. Pathogens. 2014;3:563-576. [PMID: 25438012 DOI: 10.3390/pathogens3030563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
63 Chen J, Li G, Meng H, Fan Y, Song Y, Wang S, Zhu F, Guo C, Zhang L, Shi Y. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother. 2012;61:101-108. [PMID: 21853301 DOI: 10.1007/s00262-011-1094-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
64 Viganò S, Perreau M, Pantaleo G, Harari A. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol 2012;2012:485781. [PMID: 22548114 DOI: 10.1155/2012/485781] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
65 Li B, Yan C, Zhu J, Chen X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Jiang W, Fang W. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. Front Immunol 2020;11:1037. [PMID: 32547550 DOI: 10.3389/fimmu.2020.01037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
66 Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 2012;24:213-6. [PMID: 22226204 DOI: 10.1016/j.coi.2011.12.005] [Cited by in Crossref: 119] [Cited by in F6Publishing: 117] [Article Influence: 11.9] [Reference Citation Analysis]
67 Gai L, Liu H, Cui JH, Yu W, Ding XD. The allele combinations of three loci based on, liver, stomach cancers, hematencephalon, COPD and normal population: A preliminary study. Gene 2017;605:123-30. [PMID: 28042088 DOI: 10.1016/j.gene.2016.12.031] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
68 Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011;32:345-349. [PMID: 21697013 DOI: 10.1016/j.it.2011.05.003] [Cited by in Crossref: 154] [Cited by in F6Publishing: 155] [Article Influence: 14.0] [Reference Citation Analysis]
69 Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, Wang H, Lou M, Wang FS, Lv JY, Yang YP. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011;6:e23621. [PMID: 21912640 DOI: 10.1371/journal.pone.0023621] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 9.1] [Reference Citation Analysis]
70 Hato T, Zhu AX, Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy 2016;8:299-313. [PMID: 26865127 DOI: 10.2217/imt.15.126] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 11.3] [Reference Citation Analysis]
71 Singh V, Khurana A, Allawadhi P, Banothu AK, Bharani KK, Weiskirchen R. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Front Pharmacol 2021;12:790963. [PMID: 35002724 DOI: 10.3389/fphar.2021.790963] [Reference Citation Analysis]
72 Marcq E, Pauwels P, van Meerbeeck JP, Smits EL. Targeting immune checkpoints: New opportunity for mesothelioma treatment? Cancer Treat Rev 2015;41:914-24. [PMID: 26433514 DOI: 10.1016/j.ctrv.2015.09.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
73 Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014;14:1205-1218. [PMID: 25199765 DOI: 10.1586/14737140.2014.949246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
74 Wu Y, Ding Y, Shen C. A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus. Vaccines 2022;10:257. [DOI: 10.3390/vaccines10020257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, Lasarte JJ, Pivette P, Trochon-joseph V, Vasseur B, Dixon G, Sangro B, Sarobe P. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother 2019;68:379-93. [DOI: 10.1007/s00262-018-2283-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
76 Tan-Garcia A, Wai LE, Zheng D, Ceccarello E, Jo J, Banu N, Khakpoor A, Chia A, Tham CYL, Tan AT. Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease. J Hepatol. 2017;67:490-500. [PMID: 28483682 DOI: 10.1016/j.jhep.2017.04.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
77 Behboudi S, Pereira SP. Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. World J Hepatol 2010; 2(7): 256-260 [PMID: 21161007 DOI: 10.4254/wjh.v2.i7.256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
78 Wirth TC. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. Expert Rev Gastroenterol Hepatol. 2014;8:101-110. [PMID: 24410473 DOI: 10.1586/17474124.2014.862497] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
79 Gianchecchi E, Fierabracci A. Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. Front Immunol 2018;9:2374. [PMID: 30386337 DOI: 10.3389/fimmu.2018.02374] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 17.0] [Reference Citation Analysis]
80 Nie J, Zhang Y, Li X, Chen M, Liu C, Han W. DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire. Oncotarget. 2016;7:37882-37892. [PMID: 27191266 DOI: 10.18632/oncotarget.9352] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
81 Li N, Fan X, Wang X, Deng H, Zhang K, Zhang X, Wang Y, Han Q, Lv Y, Liu Z. PRDM1 levels are associated with clinical diseases in chronic HBV infection and survival of patients with HBV-related hepatocellular carcinoma. Int Immunopharmacol 2019;73:156-62. [PMID: 31100710 DOI: 10.1016/j.intimp.2019.05.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
82 Belai EB, de Oliveira CE, Gasparoto TH, Ramos RN, Torres SA, Garlet GP, Cavassani KA, Silva JS, Campanelli AP. PD-1 blockage delays murine squamous cell carcinoma development. Carcinogenesis 2014;35:424-31. [PMID: 24031027 DOI: 10.1093/carcin/bgt305] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
83 Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011;32:345-349. [PMID: 21697013 DOI: 10.10 16/j.it.2011.05.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis 2015;6:e1792. [PMID: 26086965 DOI: 10.1038/cddis.2015.162] [Cited by in Crossref: 360] [Cited by in F6Publishing: 345] [Article Influence: 51.4] [Reference Citation Analysis]
85 Song B, Zhen S, Meng F. T cell inflammation profile after surgical resection may predict tumor recurrence in HBV-related hepatocellular carcinoma. Int Immunopharmacol 2016;41:35-41. [PMID: 27792920 DOI: 10.1016/j.intimp.2016.10.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
86 Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, Wang HK, Tsang SW, Goodwin T, Liu R, Huang L, Chen Z, Sung JJ, Chow KL, To KF, Cheng AS. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut 2018;67:931-44. [PMID: 28939663 DOI: 10.1136/gutjnl-2017-314032] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 19.3] [Reference Citation Analysis]
87 Deng Y, Wang F, Hughes T, Yu J. FOXOs in cancer immunity: Knowns and unknowns. Semin Cancer Biol 2018;50:53-64. [PMID: 29309928 DOI: 10.1016/j.semcancer.2018.01.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
88 Zhao Q, Zhang GL, Zhu X, Su D, Huang ZL, Hu ZX, Peng L. The paradoxical changes of membrane and soluble herpes virus entry mediator in hepatocellular carcinoma patients. J Gastroenterol Hepatol 2017;32:1520-4. [PMID: 27987232 DOI: 10.1111/jgh.13678] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
89 Zhou CB, Li ZW. Progress in understanding the role of PD-1/PD-L1 signaling pathway in the immunoregulation of HBV infection. Shijie Huaren Xiaohua Zazhi 2011; 19(26): 2752-2759 [DOI: 10.11569/wcjd.v19.i26.2752] [Reference Citation Analysis]
90 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
91 Li Z, Li N, Zhu Q, Zhang G, Han Q, Zhang P, Xun M, Wang Y, Zeng X, Yang C, Liu Z. Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection. Infect Genet Evol. 2013;14:240-246. [PMID: 23291409 DOI: 10.1016/j.meegid.2012.12.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
92 Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology 2014;60:1776-82. [PMID: 24912948 DOI: 10.1002/hep.27246] [Cited by in Crossref: 145] [Cited by in F6Publishing: 139] [Article Influence: 18.1] [Reference Citation Analysis]
93 Yang SZ, Zhang W, Yuan WS, Dong JH. Recurrence of Hepatocellular Carcinoma With Epithelial-Mesenchymal Transition After Spontaneous Regression: A Case Report. Medicine (Baltimore) 2015;94:e1062. [PMID: 26181539 DOI: 10.1097/MD.0000000000001062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
94 Li S, Li N, Yang S, Deng H, Li Y, Wang Y, Yang J, Lv J, Dong L, Yu G, Hou X, Wang G. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. International Immunopharmacology 2022;109:108842. [DOI: 10.1016/j.intimp.2022.108842] [Reference Citation Analysis]
95 Li K, Song Y, Qin L, Li A, Jiang S, Ren L, Zang C, Sun J, Zhao Y, Zhang Y. A CpG Methylation Signature as a Potential Marker for Early Diagnosis of Hepatocellular Carcinoma From HBV-Related Liver Disease Using Multiplex Bisulfite Sequencing. Front Oncol 2021;11:756326. [PMID: 34745991 DOI: 10.3389/fonc.2021.756326] [Reference Citation Analysis]
96 Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, Mulawadi FH, Wong KF, Liu AM, Poon RT, Fan ST, Chan KL, Gong Z, Hu Y, Lin Z, Wang G, Zhang Q, Barber TD, Chou WC, Aggarwal A, Hao K, Zhou W, Zhang C, Hardwick J, Buser C, Xu J, Kan Z, Dai H, Mao M, Reinhard C, Wang J, Luk JM. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44:765-769. [PMID: 22634754 DOI: 10.1038/ng.2295] [Cited by in Crossref: 541] [Cited by in F6Publishing: 533] [Article Influence: 54.1] [Reference Citation Analysis]
97 Shirabe K, Motomura T, Muto J, Toshima T, Matono R, Mano Y, Takeishi K, Ijichi H, Harada N, Uchiyama H. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Int J Clin Oncol. 2010;15:552-558. [PMID: 20963618 DOI: 10.1007/s10147-010-0131-0.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer 2019;8:41-65. [PMID: 30815394 DOI: 10.1159/000490360] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
99 Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, Li J. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Mol Ther 2021;29:1794-807. [PMID: 33484968 DOI: 10.1016/j.ymthe.2021.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
100 Li FJ, Zhang Y, Jin GX, Yao L, Wu DQ. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett. 2013;150:116-122. [PMID: 23261718 DOI: 10.1016/j.imlet.2012.12.004] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 7.0] [Reference Citation Analysis]
101 Korangy F, Höchst B, Manns MP, Greten TF. Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2010;4:345-53. [PMID: 20528121 DOI: 10.1586/egh.10.18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
102 Fan PW, Huang L, Chang XM, Feng YN, Yao X, Peng YC, Dong T, Wang RZ. Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood. Chin Med J (Engl) 2018;131:1289-95. [PMID: 29786040 DOI: 10.4103/0366-6999.232791] [Reference Citation Analysis]
103 Cariani E, Missale G. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver Int. 2019;39:1608-1621. [PMID: 31314948 DOI: 10.1111/liv.14192] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
104 Tan AT, Schreiber S. Adoptive T-cell therapy for HBV-associated HCC and HBV infection. Antiviral Research 2020;176:104748. [DOI: 10.1016/j.antiviral.2020.104748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
105 Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol. 2011;55:103-110. [PMID: 21145860 DOI: 10.1016/j.jhep.2010.10.025] [Cited by in Crossref: 134] [Cited by in F6Publishing: 137] [Article Influence: 11.2] [Reference Citation Analysis]
106 Omori R, Eguchi J, Hiroishi K, Ishii S, Hiraide A, Sakaki M, Doi H, Kajiwara A, Ito T, Kogo M, Imawari M. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors. Cancer Gene Ther 2012;19:637-43. [PMID: 22790963 DOI: 10.1038/cgt.2012.42] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
107 Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Immune Checkpoint Inhibitors in the Treatment of HCC. Front Oncol 2020;10:601240. [PMID: 33585218 DOI: 10.3389/fonc.2020.601240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
108 Zhang Z, Liang Y, Zhong D, Dai Z, Shang J, Lai C, Zou H, Yao Y, Feng T, Huang X. Prognostic value of inflammation‐immunity‐nutrition score in patients with hepatocellular carcinoma treated with anti‐PD‐1 therapy. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24336] [Reference Citation Analysis]
109 Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 2016;57:2359-69. [PMID: 26758422 DOI: 10.3109/10428194.2015.1135431] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
110 Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids 2013;2:e114. [PMID: 23941866 DOI: 10.1038/mtna.2013.43] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 7.6] [Reference Citation Analysis]
111 O'Neill C, Cassidy FC, O'Shea D, Hogan AE. Mucosal Associated Invariant T Cells in Cancer-Friend or Foe? Cancers (Basel) 2021;13:1582. [PMID: 33808058 DOI: 10.3390/cancers13071582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Sprinzl MF, Galle PR. Facing the dawn of immunotherapy for hepatocellular carcinoma. Journal of Hepatology 2013;59:9-10. [DOI: 10.1016/j.jhep.2013.04.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
113 Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187-2194. [PMID: 20819927 DOI: 10.1084/jem.20100643] [Cited by in Crossref: 1096] [Cited by in F6Publishing: 1055] [Article Influence: 91.3] [Reference Citation Analysis]
114 Mei J, Sun XQ, Lin WP, Li SH, Lu LH, Zou JW, Wei W, Guo RP. Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy. J Inflamm Res 2021;14:3879-90. [PMID: 34408469 DOI: 10.2147/JIR.S325600] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420-1429. [PMID: 25733155 DOI: 10.1016/j.jhep.2015.02.038] [Cited by in Crossref: 139] [Cited by in F6Publishing: 151] [Article Influence: 19.9] [Reference Citation Analysis]
116 Brinck-Jensen NS, Vorup-Jensen T, Leutscher PD, Erikstrup C, Petersen E. Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV. BMC Immunol 2015;16:65. [PMID: 26526193 DOI: 10.1186/s12865-015-0127-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]